|
1
|
Ostrom QT, Gittleman H, Fulop J, Liu M,
Blanda R, Kromer C, Wolinsky Y, Kruchko C and Barnholtz-Sloan JS:
CBTRUS statistical report: Primary brain and central nervous system
tumors diagnosed in the united states in 2008–2012. Neuro Oncol. 17
(Suppl 4):iv1–iv62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thakkar JP, Dolecek TA, Horbinski C,
Ostrom QT, Lightner DD, Barnholtz-Sloan JS and Villano JL:
Epidemiologic and molecular prognostic review of glioblastoma.
Cancer Epidemiol Biomarkers Prev. 23:1985–1996. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wick W, Osswald M, Wick A and Winkler F:
Treatment of glioblastoma in adults. Ther Adv Neurol Disorder.
11:17562864187904522018.
|
|
4
|
Dresemann G: Temozolomide in malignant
glioma. OncoTargets Ther. 3:139–146. 2010. View Article : Google Scholar
|
|
5
|
Mutter N and Stupp R: Temozolomide: A
milestone in neuro-oncology and beyond? Expert Rev Anticancer Ther.
6:1187–1204. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cabrini G, Fabbri E, Lo Nigro C, Dechecchi
MC and Gambari R: Regulation of expression of
O6-methylguanine-DNA methyltransferase and the treatment
of glioblastoma (Review). Int J Oncol. 47:417–428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoshimoto K, Mizoguchi M, Hata N, Murata
H, Hatae R, Amano T, Nakamizo A and Sasaki T: Complex DNA repair
pathways as possible therapeutic targets to overcome temozolomide
resistance in glioblastoma. Front Oncol. 2:1862012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wallace SS, Murphy DL and Sweasy JB: Base
excision repair and cancer. Cancer Lett. 327:73–89. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Montaldi AP and Sakamoto-Hojo ET:
Methoxyamine sensitizes the resistant glioblastoma T98G cell line
to the alkylating agent temozolomide. Clin Exp Med. 13:279–288.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Montaldi AP, Godoy PR and Sakamoto-Hojo
ET: APE1/REF-1 down-regulation enhances the cytotoxic effects of
temozolomide in a resistant glioblastoma cell line. Mutat Res Genet
Toxicol Environ Mutagen. 793:19–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu L and Gerson SL: Therapeutic impact of
methoxyamine: Blocking repair of abasic sites in the base excision
repair pathway. Curr Opin Investig Drugs. 5:623–627.
2004.PubMed/NCBI
|
|
12
|
Lord CJ, Tutt AN and Ashworth A: Synthetic
lethality and cancer therapy: Lessons learned from the development
of PARP inhibitors. Annu Rev Med. 66:455–470. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hartwell LH, Szankasi P, Roberts CJ,
Murray AW and Friend SH: Integrating genetic approaches into the
discovery of anticancer drugs. Science. 278:1064–1068. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bhattacharjee S and Nandi S: DNA damage
response and cancer therapeutics through the lens of the fanconi
anemia DNA repair pathway. Cell Commun Signal. 15:412017.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bryant HE, Schultz N, Thomas HD, Parker
KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ and Helleday T:
Specific killing of BRCA2-deficient tumours with inhibitors of
poly(ADP-ribose) polymerase. Nature. 434:913–917. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Farmer H, McCabe N, Lord CJ, Tutt AN,
Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I,
Knights C, et al: Targeting the DNA repair defect in BRCA mutant
cells as a therapeutic strategy. Nature. 434:917–921. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Helleday T: The underlying mechanism for
the PARP and BRCA synthetic lethality: Clearing up the
misunderstandings. Mol Oncol. 5:387–393. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mendes-Pereira AM, Martin SA, Brough R,
McCarthy A, Taylor JR, Kim JS, Waldman T, Lord CJ and Ashworth A:
Synthetic lethal targeting of PTEN mutant cells with PARP
inhibitors. EMBO Mol Med. 1:315–322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Weston VJ, Oldreive CE, Skowronska A,
Oscier DG, Pratt G, Dyer MJ, Smith G, Powell JE, Rudzki Z, Kearns
P, et al: The PARP inhibitor olaparib induces significant killing
of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood.
116:4578–4587. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Verhaak RG, Hoadley KA, Purdom E, Wang V,
Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al:
Cancer genome atlas research network: Integrated genomic analysis
identifies clinically relevant subtypes of glioblastoma
characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.
Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Salmena L, Carracedo A and Pandolfi PP:
Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shen WH, Balajee AS, Wang J, Wu H, Eng C,
Pandolfi PP and Yin Y: Essential role for nuclear PTEN in
maintaining chromosomal integrity. Cell. 128:157–170. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lester A, Rapkins R, Nixdorf S, Khasraw M
and McDonald K: Combining PARP inhibitors with radiation therapy
for the treatment of glioblastoma: Is PTEN predictive of response?
Clin Transl Oncol. 19:273–278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Quiros S, Roos WP and Kaina B: Rad51 and
BRCA2-New molecular targets for sensitizing glioma cells to
alkylating anticancer drugs. PLoS One. 6:e271832011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Filippi-Chiela EC, Thomé MP, Bueno e Silva
MM, Pelegrini AL, Ledur PF, Garicochea B, Zamin LL and Lenz G:
Resveratrol abrogates the temozolomide-induced G2 arrest leading to
mitotic catastrophe and reinforces the temozolomide-induced
senescence in glioma cells. BMC Cancer. 13:1472013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hermisson M, Klumpp A, Wick W, Wischhusen
J, Nagel G, Roos W, Kaina B and Weller M: O6-methylguanine DNA
methyltransferase and p53 status predict temozolomide sensitivity
in human malignant glioma cells. J Neurochem. 96:766–776. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ishii N, Maier D, Merlo A, Tada M,
Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of
TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human
glioma cell lines. Brain Pathol. 9:469–479. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ostermann S, Csajka C, Buclin T, Leyvraz
S, Lejeune F, Decosterd LA and Stupp R: Plasma and cerebrospinal
fluid population pharmacokinetics of temozolomide in malignant
glioma patients. Clin Cancer Res. 10:3728–3736. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Patel M, McCully C, Godwin K and Balis FM:
Plasma and cerebrospinal fluid pharmacokinetics of intravenous
temozolomide in non-human primates. J Neurooncol. 61:203–207. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cimmino G, Pepe S, Laus G, Chianese M,
Prece D, Penitente R and Quesada P: Poly(ADPR)polymerase-1
signalling of the DNA damage induced by DNA topoisomerase I poison
in D54(p53wt) and U251(p53mut) glioblastoma cell lines. Pharmacol
Res. 55:49–56. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sabisz M, Wesierska-Gadek J and
Skladanowski A: Increased cytotoxicity of an unusual DNA
topoisomerase II inhibitor compound C-1305 toward HeLa cells with
downregulated PARP-1 activity results from re-activation of the p53
pathway and modulation of mitotic checkpoints. Biochem Pharmacol.
79:1387–1397. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang J, Stevens MF, Laughton CA,
Madhusudan S and Bradshaw TD: Acquired resistance to temozolomide
in glioma cell lines: Molecular mechanisms and potential
translational applications. Oncology. 78:103–114. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cieślar-Pobuda A, Saenko Y and
Rzeszowska-Wolny J: PARP-1 inhibition induces a late increase in
the level of reactive oxygen species in cells after ionizing
radiation. Mutat Res. 732:9–15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sabbatino F, Fusciello C, Somma D, Pacelli
R, Poudel R, Pepin D, Leonardi A, Carlomagno C, Della Vittoria
Scarpati G, Ferrone S and Pepe S: Effect of p53 activity on the
sensitivity of human glioblastoma cells to PARP-1 inhibitor in
combination with topoisomerase I inhibitor or radiation. Cytometry
A. 85:953–961. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Franken NA, Rodermond HM, Stap J, Haveman
J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc.
1:2315–2319. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Atkins RJ, Ng W, Stylli SS, Hovens CM and
Kaye AH: Repair mechanisms help glioblastoma resist treatment. J
Clin Neurosci. 22:14–20. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sandhu SK, Yap TA and de Bono JS:
Poly(ADP-ribose) polymerase inhibitors in cancer treatment: A
clinical perspective. Eur J Cancer. 46:9–20. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Majuelos-Melguizo J, Rodríguez MI,
López-Jiménez L, Rodríguez-Vargas JM, Martí Martín-Consuegra JM,
Serrano-Sáenz S, Gavard J, de Almodóvar JM and Oliver FJ: PARP
targeting counteracts gliomagenesis through induction of mitotic
catastrophe and aggravation of deficiency in homologous
recombination in PTEN-mutant glioma. Oncotarget. 6:4790–4803. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tentori L, Ricci-Vitiani L, Muzi A,
Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P
and Graziani G: Pharmacological inhibition of poly(ADP-ribose)
polymerase-1 modulates resistance of human glioblastoma stem cells
to temozolomide. BMC Cancer. 14:1512014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Erice O, Smith MP, White R, Goicoechea I,
Barriuso J, Jones C, Margison GP, Acosta JC, Wellbrock C and
Arozarena I: MGMT expression predicts PARP-mediated resistance to
temozolomide. Mol Cancer Ther. 14:1236–1246. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gupta A, Yang Q, Pandita RK, Hunt CR,
Xiang T, Misri S, Zeng S, Pagan J, Jeffery J, Puc J, et al: Cell
cycle checkpoint defects contribute to genomic instability in PTEN
deficient cells independent of DNA DSB repair. Cell Cycle.
8:2198–2210. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Balvers RK, Lamfers ML, Kloezeman JJ,
Kleijn A, Berghauser Pont LM, Dirven CM and Leenstra S: ABT-888
enhances cytotoxic effects of temozolomide independent of MGMT
status in serum free cultured glioma cells. J Transl Med.
13:742015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Godoy PR, Mello SS, Magalhães DA, Donaires
FS, Nicolucci P, Donadi EA, Passos GA and Sakamoto-Hojo ET:
Ionizing radiation-induced gene expression changes in TP53
proficient and deficient glioblastoma cell lines. Mutat Res.
756:46–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zaky A, Busso C, Izumi T, Chattopadhyay R,
Bassiouny A, Mitra S and Bhakat KK: Regulation of the human
AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53
in response to DNA damage. Nucleic Acids Res. 36:1555–1566. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Poletto M, Legrand AJ, Fletcher SC and
Dianov GL: P53 coordinates base excision repair to prevent genomic
instability. Nucleic Acids Res. 44:3165–3175. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ströbel T, Madlener S, Tuna S, Vose S,
Lagerweij T, Wurdinger T, Vierlinger K, Wöhrer A, Price BD, Demple
B, et al: Ape1 guides DNA repair pathway choice that is associated
with drug tolerance in glioblastoma. Sci Rep. 7:96742017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ming M and He YY: PTEN in DNA damage
repair. Cancer Lett. 319:125–129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Mukherjee A and Karmakar P: Attenuation of
PTEN perturbs genomic stability via activation of Akt and
down-regulation of Rad51 in human embryonic kidney cells. Mol
Carcinog. 52:611–618. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hunt CR, Gupta A, Horikoshi N and Pandita
TK: Does PTEN loss impair DNA double-strand break repair by
homologous recombination? Clin Cancer Res. 18:920–922. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fu D, Calvo JA and Samson LD: Balancing
repair and tolerance of DNA damage caused by alkylating agents. Nat
Rev Cancer. 12:104–120. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Schuhwerk H, Atteya R, Siniuk K and Wang
ZQ: PARPing for balance in the homeostasis of
poly(ADP-ribosyl)ation. Semin Cell Dev Biol. 63:81–91. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chai KM, Wang CY, Liaw HJ, Fang KM, Yang
CS and Tzeng SF: Downregulation of BRCA1-BRCA2-containing complex
subunit 3 sensitizes glioma cells to temozolomide. Oncotarget.
5:10901–10915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Ray Chaudhuri A and Nussenzweig A: The
multifaceted roles of PARP1 in DNA repair and chromatin remodelling
(Review). Nat Rev Mol Cell Biol. 18:610–621. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Polo SE and Jackson SP: Dynamics of DNA
damage response proteins at DNA breaks: A focus on protein
modifications. Genes Dev. 25:409–433. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nagel ZD, Kitange GJ, Gupta SK, Joughin
BA, Chaim IA, Mazzucato P, Lauffenburger DA, Sarkaria JN and Samson
LD: DNA repair capacity in multiple pathways predicts
chemoresistance in glioblastoma multiforme. Cancer Res. 77:198–206.
2017. View Article : Google Scholar : PubMed/NCBI
|
